HomeCompareKINUF vs PFE

KINUF vs PFE: Dividend Comparison 2026

KINUF yields 1.70% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KINUF wins by $36.3K in total portfolio value
10 years
KINUF
KINUF
● Live price
1.70%
Share price
$20.62
Annual div
$0.35
5Y div CAGR
49.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$85.8K
Annual income
$28,470.84
Full KINUF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — KINUF vs PFE

📍 KINUF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKINUFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KINUF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KINUF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KINUF
Annual income on $10K today (after 15% tax)
$144.91/yr
After 10yr DRIP, annual income (after tax)
$24,200.21/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, KINUF beats the other by $1,880.31/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KINUF + PFE for your $10,000?

KINUF: 50%PFE: 50%
100% PFE50/50100% KINUF
Portfolio after 10yr
$67.7K
Annual income
$27,364.78/yr
Blended yield
40.43%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

KINUF
No analyst data
Altman Z
1.2
Piotroski
6/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KINUF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKINUFPFE
Forward yield1.70%6.13%
Annual dividend / share$0.35$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR49.9%13.2%
Portfolio after 10y$85.8K$49.6K
Annual income after 10y$28,470.84$26,258.71
Total dividends collected$60.4K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: KINUF vs PFE ($10,000, DRIP)

YearKINUF PortfolioKINUF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$10,956$255.56$9,153$693.39+$1.8KKINUF
2$12,115$392.24$8,593$849.25+$3.5KKINUF
3$13,570$607.63$8,336$1,066.78+$5.2KKINUF
4$15,474$953.54$8,437$1,384.80+$7.0KKINUF
5$18,080$1,523.22$9,013$1,875.40+$9.1KKINUF
6$21,839$2,493.37$10,306$2,680.72+$11.5KKINUF
7$27,587$4,219.27$12,820$4,101.38+$14.8KKINUF
8$36,985$7,466.67$17,673$6,826.70+$19.3KKINUF
9$53,598$14,023.69$27,543$12,591.86+$26.1KKINUF
10$85,820$28,470.84$49,560$26,258.71+$36.3KKINUF

KINUF vs PFE: Complete Analysis 2026

KINUFStock

Kintetsu Group Holdings Co.,Ltd. engages in the transportation, real estate, distribution, hotel, and leisure businesses in Japan and internationally. The company offers railway, bus and taxi, logistics, marine, and other transportation services. It is also involved in the sale, leasing, and renovation of real estate properties; and solar and agricultural businesses. In addition, the company operates department stores; stores; convenience stores, cafes, drug stores, general merchandise stores, supermarkets, etc.; restaurants and others in the service and parking areas of expressways; and hotels under the Miyako Hotels & Resorts brand, as well as resorts and leisure facilities. Further, it engages in the tourism, travel, manufacturing and construction, and other service businesses. The company was formerly known as Kintetsu Corporation and changed its name to Kintetsu Group Holdings Co.,Ltd. in April 2015. Kintetsu Group Holdings Co.,Ltd. was founded in 1910 and is headquartered in Osaka, Japan.

Full KINUF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this KINUF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KINUF vs SCHDKINUF vs JEPIKINUF vs OKINUF vs KOKINUF vs MAINKINUF vs JNJKINUF vs MRKKINUF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.